Neuland Laboratories Limited.

BSE: NEULANDLAB524558ISIN INE794A01010

Healthcare
Pharmaceuticals
BSE 500

Share price

₹19,614.30+179.10 (+0.92%)

as of 4 Nov 2026

Prices adjusted for splits and bonuses; cash dividends excluded. Volume shows actual shares traded.

52W high: ₹24,235.05
52W low: ₹11,500.00
Off 52W high: -19.07%
1M return: -10.26%
3M return: -1.76%
6M return: +15.57%
1Y return: +11.40%
20D avg volume: 3,873
50 DMA: ₹21,521.12
200 DMA: ₹17,472.22

Key ratios Consolidated

Market cap: ₹25,165 Cr
Current price: ₹19,614.30
52W high / low: ₹24,235.05 / ₹11,500.00
Face value: ₹10.00
P/E: 55.61
P/B: 12.47
EPS (TTM): ₹352.73
Book value / share: ₹1,573.36
ROE: —
ROCE: 23.10%
Operating margin: —
Net margin: —
Debt / equity: 0.10
Net debt: ₹119.95 Cr
Interest cover: 21.42
Dividend yield: 0.17%
Dividend / share (TTM): ₹34.00
Payout: 9.64%
Cash conversion cycle: 141.2 days

Financials

Metric	Q2 FY27	Q1 FY27	Q4 FY26	Q3 FY26	Q2 FY26	Q1 FY26	Q4 FY25	Q3 FY25	Q2 FY25	Q1 FY25	Q4 FY24	Q3 FY24
Income statement
	449.66	641.58	776.25	439.71	514.27	292.75	328.36	398.03	310.84	439.60	385.01	392.83
	7.50	8.49	12.46	8.05	1.80	7.86	7.46	3.91	4.33	4.81	5.36	2.10
	457.15	650.07	788.71	447.76	516.07	300.61	335.82	401.94	315.18	444.41	390.37	394.93
	388.17	452.22	501.21	393.29	386.64	283.04	296.52	329.95	265.75	335.19	298.17	290.45
	215.79	228.77	230.79	199.86	227.64	161.48	141.24	145.44	133.17	154.95	174.98	153.45
	0.00	0.00	0.00	0.00	0.00	0.00	0.00	—	—	—	—	—
	101.76	106.43	98.47	88.83	80.37	73.47	66.46	69.34	63.07	73.14	62.49	65.73
	7.31	6.97	7.21	6.79	5.37	4.58	2.35	2.22	1.06	2.67	3.61	3.74
	28.77	26.56	25.09	23.92	22.54	20.19	16.89	16.30	16.07	16.28	16.46	15.14
	99.28	91.23	101.16	84.69	94.75	71.25	83.93	36.37	25.79	30.07	35.58	27.25
	68.98	197.85	287.50	54.48	129.44	17.57	39.30	71.99	49.42	109.22	92.20	104.48
	0.00	0.00	0.00	0.00	0.00	0.00	0.00	55.78	0.00	20.63	0.00	0.00
	68.98	197.85	287.50	54.48	129.44	17.57	39.30	127.77	49.42	129.84	92.20	104.48
	17.35	50.17	74.82	13.90	32.58	3.67	11.49	26.18	16.58	31.97	24.64	23.09
	51.62	147.67	212.67	40.57	96.85	13.90	27.81	101.59	32.84	97.87	67.56	81.39
	40.24	115.10	165.76	31.62	75.49	10.83	21.67	79.18	25.60	76.28	52.66	63.44
Key metrics
	105.06	231.38	319.80	85.19	157.35	42.34	58.54	146.29	66.55	148.79	112.27	123.36
	23.40%	36.10%	41.20%	19.40%	30.60%	14.50%	17.80%	36.80%	21.40%	33.80%	29.20%	31.40%
	11.50%	23.00%	27.40%	9.20%	18.80%	4.70%	8.50%	25.50%	10.60%	22.30%	17.50%	20.70%
	3.20%	—	13.30%	—	7.10%	—	2.40%	—	—	—	—	—
	-12.60%	119.20%	136.40%	10.50%	65.40%	-33.40%	-14.70%	1.30%	—	—	—	—
	-46.70%	962.40%	664.70%	-60.10%	194.90%	-85.80%	-58.80%	24.80%	—	—	—	—

Metric	TTM	FY26	FY25	FY24	FY23	FY22	FY21	FY20	FY19	FY18
Income statement
	2,307	2,023	1,477	1,559	1,191	951.08	936.91	762.71	666.83	529.16
	36.50	30.17	20.51	12.54	9.75	2.08	16.09	3.89	3.49	4.54
	2,344	2,053	1,497	1,571	1,201	953.15	953.01	766.60	670.32	533.70
	1,735	1,564	1,227	1,170	985.20	870.99	847.67	713.67	649.98	519.76
	875.21	819.76	574.81	632.43	487.74	437.55	439.66	391.36	360.44	281.09
	0.00	0.00	0.00	—	—	—	—	—	—	—
	395.49	341.14	272.00	257.06	201.79	182.47	149.74	123.56	110.46	—
	28.28	23.95	8.30	14.00	13.07	13.49	17.90	21.57	15.66	18.93
	104.34	91.74	65.55	59.70	52.78	49.04	39.68	31.28	25.86	—
	376.36	351.84	293.94	105.13	103.78	—	81.66	59.47	54.85	54.13
	608.81	488.98	269.93	401.44	215.75	82.16	105.33	52.92	20.34	13.93
	0.00	0.00	76.40	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	608.81	488.98	346.33	401.44	215.75	82.16	105.33	52.92	20.34	13.93
	156.24	124.98	86.22	101.36	52.23	18.34	24.70	36.71	3.90	1.87
	452.53	364.00	260.11	300.08	163.52	63.82	80.63	16.21	16.44	12.06
	352.72	283.71	202.74	233.89	127.45	49.74	62.85	12.63	13.06	—
Key metrics
	741.43	604.67	420.18	475.14	281.60	144.69	162.91	105.77	61.86	32.86
	32.14%	29.90%	28.50%	30.50%	23.60%	15.20%	17.40%	13.90%	9.30%	6.20%
	19.61%	18.00%	17.60%	19.30%	13.70%	6.70%	8.60%	2.10%	2.50%	2.30%
	—	23.10%	20.70%	—	—	—	—	—	—	—
	50.46%	37.00%	-5.20%	30.80%	25.20%	1.50%	22.80%	14.40%	26.00%	—
	88.44%	39.90%	-13.30%	83.50%	156.20%	-20.80%	397.40%	-1.40%	36.30%	—
	—	-43.49	110.92	—	—	—	—	—	—	—
	—	0.95	1.22	—	—	—	—	—	—	—
	—	0.10	0.09	—	—	—	—	—	—	—
	—	119.95	4.08	—	—	—	—	—	—	—
	—	141.2	111.0	—	—	—	—	—	—	—
Balance sheet
	—	2,930	2,180	—	—	—	—	—	—	—
	—	1,483	1,140	—	—	—	—	—	—	—
	—	76.67	131.93	—	—	—	—	—	—	—
	—	541.35	315.72	—	—	—	—	—	—	—
	—	510.29	385.76	—	—	—	—	—	—	—
	—	72.19	69.30	—	—	—	—	—	—	—
	—	892.29	673.71	—	—	—	—	—	—	—
	—	269.14	252.20	—	—	—	—	—	—	—
	—	710.20	465.69	—	—	—	—	—	—	—
	—	196.62	136.01	—	—	—	—	—	—	—
	—	35.67	45.28	—	—	—	—	—	—	—
	—	160.95	90.73	—	—	—	—	—	—	—
	—	1,874	1,525	—	—	—	—	—	—	—
Cash flow
	—	346.68	317.38	—	—	—	—	—	—	—
	—	-423.73	-298.16	—	—	—	—	—	—	—
	—	20.98	24.96	—	—	—	—	—	—	—
	—	390.17	206.46	—	—	—	—	—	—	—

Metric	Q2 FY27	Q1 FY27	Q4 FY26	Q3 FY26	Q2 FY26	Q1 FY26	Q4 FY25	Q3 FY25	Q2 FY25	Q1 FY25	Q4 FY24	Q3 FY24
Income statement
	449.66	641.58	776.25	439.71	514.27	292.75	328.36	398.03	310.84	439.60	385.01	392.83
	7.49	8.49	12.46	8.05	1.80	7.86	7.46	3.91	4.33	4.81	5.36	2.10
	457.15	650.07	788.71	447.76	516.07	300.61	335.82	401.94	315.18	444.41	390.37	394.93
	388.67	452.53	501.66	393.49	387.03	283.23	296.84	330.17	266.64	334.73	298.29	291.15
	215.79	228.77	230.79	199.86	227.64	161.48	141.24	145.44	133.17	154.95	174.98	153.45
	0.00	0.00	0.00	0.00	0.00	0.00	0.00	—	—	—	—	—
	95.05	103.02	95.27	85.99	76.68	70.88	64.19	67.21	59.03	70.97	61.01	63.34
	7.31	6.97	7.23	6.79	5.34	4.58	2.35	2.22	1.06	2.67	3.61	3.74
	28.77	26.56	25.09	23.92	22.54	20.19	16.89	16.30	16.07	16.28	16.46	15.14
	106.49	94.95	104.79	87.73	98.86	74.03	86.51	38.72	30.72	31.77	37.19	30.34
	68.48	197.54	287.04	54.27	129.04	17.38	38.98	71.77	48.54	109.68	92.08	103.78
	0.00	0.00	0.00	0.00	0.00	0.00	0.00	55.78	—	20.63	—	—
	68.48	197.54	287.04	54.27	129.04	17.38	38.98	127.55	48.54	130.31	92.08	103.78
	17.35	50.17	74.52	13.86	32.58	3.67	11.25	26.15	16.58	31.97	24.47	23.08
	51.13	147.36	212.52	40.42	96.46	13.71	27.73	101.39	31.96	98.34	67.61	80.70
	39.85	114.86	165.65	31.50	75.18	10.68	21.62	79.03	24.91	76.65	52.70	62.90
Key metrics
	104.56	231.07	319.36	84.98	156.92	42.15	58.22	146.07	65.67	149.26	112.15	122.66
	23.30%	36.00%	41.10%	19.30%	30.50%	14.40%	17.70%	36.70%	21.10%	34.00%	29.10%	31.20%
	11.40%	23.00%	27.40%	9.20%	18.80%	4.70%	8.40%	25.50%	10.30%	22.40%	17.60%	20.50%
	3.20%	—	13.30%	—	7.10%	—	2.40%	—	—	—	—	—
	-12.60%	119.20%	136.40%	10.50%	65.40%	-33.40%	-14.70%	1.30%	—	—	—	—
	-47.00%	974.80%	666.40%	-60.10%	201.80%	-86.10%	-59.00%	25.60%	—	—	—	—

Metric	TTM	FY26	FY25	FY24	FY23	FY22	FY21	FY20	FY19	FY18
Income statement
	2,307	2,023	1,477	1,559	1,191	951.08	936.91	762.71	666.83	529.16
	36.49	30.16	20.51	12.54	9.75	2.08	16.09	3.89	3.49	4.54
	2,344	2,053	1,497	1,571	1,201	953.15	953.01	766.60	670.32	533.70
	1,736	1,565	1,228	1,170	985.73	871.41	848.05	714.10	650.49	520.16
	875.21	819.76	574.81	632.43	487.74	437.55	439.66	391.36	360.44	281.09
	0.00	0.00	0.00	—	—	—	—	—	—	—
	379.33	328.82	261.40	248.53	194.84	175.76	144.02	118.48	104.47	—
	28.30	23.95	8.30	14.00	13.07	13.49	17.90	21.57	15.66	18.92
	104.34	91.73	65.54	59.70	52.78	49.04	39.68	31.28	25.86	22.10
	393.96	365.42	305.50	114.33	111.27	—	87.75	64.98	61.33	61.79
	607.33	487.73	268.97	400.77	215.21	81.74	104.96	52.50	19.84	13.54
	0.00	0.00	76.40	—	—	—	—	—	—	—
	607.33	487.73	345.37	400.77	215.21	81.74	104.96	52.50	19.84	13.54
	155.90	124.63	85.95	101.17	52.09	18.21	24.67	36.62	3.69	1.73
	451.43	363.11	259.43	299.60	163.12	63.53	80.30	15.88	16.14	11.81
	351.86	283.01	202.20	233.51	127.14	49.52	62.58	12.38	12.83	—
Key metrics
	739.97	603.41	419.21	474.47	281.06	144.27	162.54	105.35	61.36	54.56
	32.07%	29.80%	28.40%	30.40%	23.60%	15.20%	17.30%	13.80%	9.20%	10.30%
	19.57%	17.90%	17.60%	19.20%	13.70%	6.70%	8.60%	2.10%	2.40%	2.20%
	—	23.20%	20.70%	—	—	—	—	—	—	—
	50.46%	37.00%	-5.20%	30.80%	25.20%	1.50%	22.80%	14.40%	26.00%	—
	88.65%	40.00%	-13.40%	83.70%	156.80%	-20.90%	405.70%	-1.60%	36.70%	—
	—	-42.59	111.04	—	—	—	—	—	—	—
	—	0.96	1.22	—	—	—	—	—	—	—
	—	0.11	0.09	—	—	—	—	—	—	—
	—	121.31	5.63	—	—	—	—	—	—	—
	—	139.5	108.8	—	—	—	—	—	—	—
Balance sheet
	—	2,928	2,178	—	—	—	—	—	—	—
	—	1,481	1,138	—	—	—	—	—	—	—
	—	75.31	130.38	—	—	—	—	—	—	—
	—	541.35	315.72	—	—	—	—	—	—	—
	—	510.29	385.76	—	—	—	—	—	—	—
	—	71.79	69.17	—	—	—	—	—	—	—
	—	892.27	673.69	—	—	—	—	—	—	—
	—	278.66	260.90	—	—	—	—	—	—	—
	—	719.24	472.84	—	—	—	—	—	—	—
	—	196.62	136.01	—	—	—	—	—	—	—
	—	35.67	45.28	—	—	—	—	—	—	—
	—	160.95	90.73	—	—	—	—	—	—	—
	—	1,866	1,518	—	—	—	—	—	—	—
Cash flow
	—	347.58	317.49	—	—	—	—	—	—	—
	—	-423.74	-298.14	—	—	—	—	—	—	—
	—	20.98	24.96	—	—	—	—	—	—	—
	—	390.17	206.45	—	—	—	—	—	—	—

Compounded growth

Standalone

Sales CAGR 3Y: +19.31%
Sales CAGR 5Y: +16.64%
Profit CAGR 3Y: +30.57%
Profit CAGR 5Y: +35.23%
Sales YoY (TTM): +50.46%
Profit YoY (TTM): +88.65%

Consolidated

Sales CAGR 3Y: +19.31%
Sales CAGR 5Y: +16.64%
Profit CAGR 3Y: +30.57%
Profit CAGR 5Y: +35.18%
Sales YoY (TTM): +50.46%
Profit YoY (TTM): +88.44%

Compounded from reported annual figures. We publish no share-price CAGR: our prices are as-traded, so one would be wrong across every split and bonus issue.

Shareholding as of 30 Sep 2026

Promoter holding: 32.27%

Quarter	September 2026	June 2026
Promoter %	32.27%	32.62%

Holder	Type	Holding	Previous	Change
Davuluri Ownership Trust (Dr. Davuluri Ramamohan Rao, Mr. Davuluri Sucheth Rao and Mr. Davuluri Saharsh Rao - Trustees)	Promoter	25.98%	25.98%	0.00%
MALABAR INDIA FUND LIMITED	Public	4.66%	5.42%	-0.76%
MUKUL MAHAVIR AGRAWAL	Public	3.12%	3.12%	0.00%
HDFC MUTUAL FUND - HDFC MNC FUND	Public	2.82%	—	—
DAVULURI SUCHETH RAO	Promoter	2.01%	2.01%	0.00%
SIDDHARTH IYER	Public	1.72%	1.67%	+0.05%
RAMAMOHAN RAO DAVULURI	Promoter	1.63%	1.63%	0.00%
DAVULURI SAHARSH RAO	Promoter	1.60%	1.52%	+0.08%
HSBC MUTUAL FUND - HSBC SMALL CAP FUND	Public	1.55%	1.55%	0.00%
ICICI PRUDENTIAL S&P BSE 500 ETF	Public	1.53%	—	—
MAHINDRA MANULIFE ELSS TAX SAVER FUND	Public	1.52%	1.93%	-0.41%
KEDIA SECURITIES PRIVATE LIMITED	Public	1.01%	1.01%	0.00%
DAVULURI ROHINI NIVEDITHA RAO	Promoter Group	0.28%	0.67%	-0.39%
GANNABATHULA VEERAVENKATA SATYANARAYANAMURTY	Promoter Group	0.24%	0.24%	0.00%
USHA RANI REDDY CHEVALLA	Promoter Group	0.17%	0.21%	-0.04%

Public shareholders are disclosed individually only above 1%.

Peer comparison

Company	Mkt cap (₹ Cr)	Price (₹)	P/E	ROCE	Sales YoY	Profit YoY	1Y return
Sun Pharmaceutical Industries Ltd.	4,26,112	1,776.00	38.78	17.90%	+12.13% TTM	+4.79% TTM	+4.92%
Divi's Laboratories Ltd.	2,66,424	10,036.00	91.09	19.00%	+16.35% TTM	+26.84% TTM	+47.61%
Torrent Pharmaceuticals Ltd.	1,79,908	4,730.00	85.71	9.10%	+42.06% TTM	-1.92% TTM	+32.24%
Laurus Labs Limited	1,24,601	2,306.10	93.53	19.70%	+23.03% TTM	+95.38% TTM	+134.59%
Zydus Lifesciences Limited	1,18,703	1,190.00	25.85	19.20%	+21.11% TTM	-2.51% TTM	+22.32%
Dr. Reddy's Laboratories Ltd.	1,14,513	1,372.00	41.50	13.90%	-3.53% TTM	-51.90% TTM	+14.26%
Cipla Ltd.	1,13,110	1,400.10	39.63	14.90%	-0.74% TTM	-47.48% TTM	-6.88%
Mankind Pharma Limited	1,04,631	2,533.15	46.22	13.70%	+13.27% TTM	+27.60% TTM	+6.91%
Aurobindo Pharma Ltd.	97,878	1,701.10	26.38	13.60%	+9.09% TTM	+9.48% TTM	+47.79%
Lupin Ltd	92,145	2,015.00	17.65	28.40%	+24.22% TTM	+20.10% TTM	+0.84%
Glenmark Pharmaceuticals ltd	70,608	2,501.85	39.27	16.20%	+32.94% TTM	+138.48% TTM	+35.48%
Alkem Laboratories Limited	62,054	5,190.00	28.15	18.80%	+13.36% TTM	-5.52% TTM	-8.38%
Abbott India Ltd. S	57,685	27,146.85	35.73	41.90%	+6.29% TTM	+11.18% TTM	-7.56%
Biocon Ltd.	56,061	344.00	134.63	2.90%	+5.70% TTM	-55.37% TTM	-9.53%
Gland Pharma Limited	52,105	3,157.70	46.16	13.70%	+17.57% TTM	+46.55% TTM	+65.09%
Ipca Laboratories Ltd.	50,051	1,973.15	36.40	16.40%	+10.59% TTM	+67.91% TTM	+52.33%
GlaxoSmithkline Pharmaceuticals Ltd.	42,904	2,532.60	37.42	55.40%	+12.12% TTM	+20.03% TTM	-4.84%
Ajanta Pharma Ltd.	41,406	3,313.55	32.79	29.40%	+25.01% TTM	+29.70% TTM	+26.89%
Emcure Pharmaceuticals Limited	41,254	2,174.55	37.75	25.10%	+21.12% TTM	+33.34% TTM	+64.07%
J.B. Chemicals & Pharmaceuticals Lt	38,731	2,412.25	47.77	21.90%	+5.87% TTM	+7.56% TTM	+45.79%
Sai Life Sciences Limited	32,855	1,546.30	90.80	18.10%	—	—	+67.49%
PIRAMAL PHARMA LIMITED	31,659	237.80	-151.21	0.80%	+9.43% TTM	-781.93% TTM	+18.60%
ACUTAAS CHEMICALS LIMITED	30,928	3,777.65	70.51	27.70%	+45.18% TTM	+95.78% TTM	+106.30%
Wockhardt Ltd	30,869	1,899.80	76.22	6.40%	+25.70% TTM	+894.12% TTM	+39.18%
RUBICON RESEARCH LIMITED	28,416	1,716.55	98.59	24.30%	—	—	+164.06%
Neuland Laboratories Limited.	25,165	19,614.30	55.61	23.10%	+50.46% TTM	+88.44% TTM	+11.40%

Filings & corporate actions

Recent announcements

Copy of Newspaper Publication4 Nov 2026 · Company Update / Newspaper Publication
Audio Recording of the Earnings call conducted on November 3, 20263 Nov 2026 · Company Update / Analyst / Investor Meet
Investor Presentation on the Financial Results of the Company for the quarter and half year ended September 30, 20263 Nov 2026 · Company Update / Investor Presentation
Press Release on the Financial Results of the Company for the quarter and half year ended September 30, 20263 Nov 2026 · Company Update / Press Release / Media Release
Disclosure under Regulation 30 of SEBI Listing Regulations3 Nov 2026 · Company Update / General
Unaudited Financial Results of the Company for the quarter and half year ended September 30, 20263 Nov 2026 · Result / Financial Results
Unaudited Financial Results of the Company for the quarter and half year ended September 30, 20263 Nov 2026 · Board Meeting / Outcome of Board Meeting
Intimation of Loss of Share Certificate(s)29 Oct 2026 · Others / Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Q2FY27 Earnings Call Intimation28 Oct 2026 · Company Update / Analyst / Investor Meet
Copy of Newspaper Publication24 Oct 2026 · Company Update / Newspaper Publication
Neuland Laboratories Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 03/11/2026 ,inter alia, to consider and approve the unaudited Financial ....22 Oct 2026 · Board Meeting / Board Meeting
We refer to our letter dated August 14, 2026 regarding the US FDA inspection conducted at our Unit 3 manufacturing facility and we would like to inform that the US FDA has issued an EIR ....14 Oct 2026 · Company Update / General
Certificate under Reg. 74(5) of SEBI (DP) Regulations, 20185 Oct 2026 · Company Update / Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
Closure of Trading Window25 Sep 2026 · Insider Trading / SAST / Closure of Trading Window
Intimation about Schedule of Analyst / Institutional Investor Meeting on September 23 - 25, 202616 Sep 2026 · Company Update / Analyst / Investor Meet
Press Release15 Sep 2026 · Company Update / Press Release / Media Release
Intimation about Schedule of Analyst / Institutional Investor Meeting on September 15, 2026 and September 17, 20269 Sep 2026 · Company Update / Analyst / Investor Meet
Disclosure under Regulation 30 of SEBI Listing Regulations7 Sep 2026 · Company Update / General
Announcement under Regulation 30 (LODR) - Credit Rating25 Aug 2026 · Company Update / Credit Rating
Copy of Newspaper Publication23 Aug 2026 · Company Update / Newspaper Publication
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Malabar India Fund Ltd17 Aug 2026 · Insider Trading / SAST / Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011
Intimation regarding completion of US FDA Inspection14 Aug 2026 · Company Update / General
Transcript of the Earnings Call conducted on August 5, 202610 Aug 2026 · Company Update / Earnings Call Transcript
Intimation about Schedule of Analyst / Institutional Investor Meeting on August 12, 20267 Aug 2026 · Company Update / Analyst / Investor Meet
Copy of Newspaper Publication6 Aug 2026 · Company Update / Newspaper Publication
Audio Recording of the Earnings call conducted on August 5, 20265 Aug 2026 · Company Update / Analyst / Investor Meet
Disclosure under Regulation 30 of SEBI Listing Regulations - Enhancement of manufacturing capacity5 Aug 2026 · Company Update / General
Disclosure under Regulation 30 of SEBI Listing Regulations - Execution of deed of Corporate Guarantee5 Aug 2026 · Company Update / General
Investor Presentation on the Financial Results of the Company for the quarter ended June 30, 20265 Aug 2026 · Company Update / Investor Presentation
Press Release on the Financial Results of the Company for the quarter ended June 30, 20265 Aug 2026 · Company Update / Press Release / Media Release
Unaudited Financial Results of the Company for the quarter ended June 30, 20265 Aug 2026 · Result / Financial Results
Unaudited Financial Results of the Company for the quarter ended June 30, 20265 Aug 2026 · Board Meeting / Outcome of Board Meeting
Voting Results, Scrutinizer Report and proceedings of 42nd Annual General Meeting held on August 4, 20264 Aug 2026 · AGM/EGM / AGM
Voting Results, Scrutinizer Report and proceeding of 42nd Annual General Meeting held on August 4, 20264 Aug 2026 · AGM/EGM / AGM
Intimation under Regulation 30 of SEBI Listing Regulations31 Jul 2026 · Company Update / General
Q1FY27 Earnings Call Intimation28 Jul 2026 · Company Update / Analyst / Investor Meet
Neuland Laboratories Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 05/08/2026 ,inter alia, to consider and approve the unaudited financial ....20 Jul 2026 · Board Meeting / Board Meeting
Intimation of Loss of Share Certificate(s)20 Jul 2026 · Others / Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Announcement under Regulation 30 (LODR) - Credit Rating13 Jul 2026 · Company Update / Credit Rating
Newspaper Publication regarding dispatch of notice of 42nd Annual General Meeting and Integrated Annual Report for FY 2025-2610 Jul 2026 · Company Update / Newspaper Publication

Corporate actions

Purpose	Ex date	Record date	Payment date
Final Dividend - Rs. - 34.0000	24 Jul 2026	24 Jul 2026	—
Final Dividend - Rs. - 12.0000	18 Jul 2025	18 Jul 2025	—
Final Dividend - Rs. - 14.0000	12 Jul 2024	—	—

Board meetings

3 Nov 2026 Board Meeting - Financial Results
5 Aug 2026 Board Meeting - Financial Results